Luigi De Cicco1, Stefano Bracelli2. 1. Department of Radiation Oncology, ASST della Valle Olona, via A. da Brescia, 1, 21052, Busto Arsizio, VA, Italy. luigi.decicco@yahoo.it. 2. Department of Radiation Oncology, ASST della Valle Olona, via A. da Brescia, 1, 21052, Busto Arsizio, VA, Italy.
Abstract
INTRODUCTION: In the external beam prostate cancer radiation therapy, daily gland displacement could lead to a target missing. The use of intra-prostatic gold fiducial markers for daily prostate position verification and correction before and during treatment delivery (image-guided radiotherapy, IGRT) is widely used in the radiation therapy centers to accurately target the prostate. Usually, the fiducial markers are implanted through the rectum, with complications such as infections and rectal bleeding. We report our experience in prostate fiducial markers implantation through a transperineal approach. PATIENTS AND METHODS: Between September 2011 and January 2018 at our center, 101 patients underwent gold seed fiducial marker transperineal ultrasound-guided implantation for prostate IGRT. We retrospectively reviewed their features and outcome. Twenty-two (21.8%) patients had previously been subjected to a transurethral prostate resection (TURP) for obstructive urinary symptoms because of benign prostatic hypertrophy. No antibiotic prophylaxis was used. RESULTS: The procedure was well tolerated. In one patient, a single episode of self-limiting urinary bleeding occurred just after it. No other complication was recorded. All the patients, at the evaluation before discharge, reported no pain or dysuria. No rectal bleeding, hematospermia, urinary obstruction or infection were reported in the next days. No markers lost or migration occurred. DISCUSSION AND CONCLUSION: According to our experience, prostate fiducial markers implantation through a transperineal approach is safe and should be recommended to limit the use of antibiotic therapy and patients morbidity. A previous TURP was not related to a higher risk of loss of seeds.
INTRODUCTION: In the external beam prostate cancer radiation therapy, daily gland displacement could lead to a target missing. The use of intra-prostatic gold fiducial markers for daily prostate position verification and correction before and during treatment delivery (image-guided radiotherapy, IGRT) is widely used in the radiation therapy centers to accurately target the prostate. Usually, the fiducial markers are implanted through the rectum, with complications such as infections and rectal bleeding. We report our experience in prostate fiducial markers implantation through a transperineal approach. PATIENTS AND METHODS: Between September 2011 and January 2018 at our center, 101 patients underwent gold seed fiducial marker transperineal ultrasound-guided implantation for prostate IGRT. We retrospectively reviewed their features and outcome. Twenty-two (21.8%) patients had previously been subjected to a transurethral prostate resection (TURP) for obstructive urinary symptoms because of benign prostatic hypertrophy. No antibiotic prophylaxis was used. RESULTS: The procedure was well tolerated. In one patient, a single episode of self-limiting urinary bleeding occurred just after it. No other complication was recorded. All the patients, at the evaluation before discharge, reported no pain or dysuria. No rectal bleeding, hematospermia, urinary obstruction or infection were reported in the next days. No markers lost or migration occurred. DISCUSSION AND CONCLUSION: According to our experience, prostate fiducial markers implantation through a transperineal approach is safe and should be recommended to limit the use of antibiotic therapy and patients morbidity. A previous TURP was not related to a higher risk of loss of seeds.
Authors: Maaike R Moman; Uulke A van der Heide; Alexis N T J Kotte; R Jeroen A van Moorselaar; Gijsbert H Bol; Stefan P G Franken; Marco van Vulpen Journal: Radiother Oncol Date: 2010-03-23 Impact factor: 6.280
Authors: D R Henderson; J R Murray; A C Tree; U Riley; N A Rosenfelder; D Murray; V S Khoo; N J van As Journal: Clin Oncol (R Coll Radiol) Date: 2015-10-09 Impact factor: 4.126
Authors: Florian M E Wagenlehner; Adrian Pilatz; Przemyslaw Waliszewski; Wolfgang Weidner; Truls E Bjerklund Johansen Journal: Nat Rev Urol Date: 2014-01-14 Impact factor: 14.432
Authors: Simon Brown; Margot Lehman; Janet Ferrari-Anderson; Alan Glyde; Elizabeth Burmeister; David Nicol Journal: J Med Imaging Radiat Oncol Date: 2011-08 Impact factor: 1.735
Authors: Ann M Henry; Cathy Wilkinson; James P Wylie; John P Logue; Pat Price; Vincent S Khoo Journal: Radiother Oncol Date: 2004-10 Impact factor: 6.280
Authors: Johan F Langenhuijsen; Emile N J T van Lin; Lambertus A Kiemeney; Lisette P van der Vight; Gill M McColl; Andries G Visser; J Alfred Witjes Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-23 Impact factor: 7.038
Authors: Jasmin Loh; Katie Baker; Swetha Sridharan; Peter Greer; Chris Wratten; Anne Capp; Sarah Gallagher; Jarad Martin Journal: Radiat Oncol Date: 2015-02-13 Impact factor: 3.481